Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
CD19 t-haNK by ImmunityBio for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
CD19 t-haNK is under clinical development by ImmunityBio and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...